Lipid nanoparticle–encapsulated mRNA therapeutic vaccine encoding HPV16/18 antigens, administered intramuscularly (25/75/150 µg; three doses every 2 weeks). It promotes dendritic-cell antigen presentation (MHC I/II) and robust CD8+ and CD4+ T-cell responses to clear HPV-infected dysplastic cervical epithelial cells and drive lesion regression.
Lipid nanoparticle–encapsulated mRNA encoding HPV16/18 antigens is taken up by host cells, translated into viral proteins, and presented on MHC I/II by dendritic and other antigen-presenting cells. This primes and expands HPV16/18-specific CD8+ cytotoxic and CD4+ helper T cells, promoting immune-mediated clearance of HPV-infected dysplastic cervical epithelial cells and lesion regression.
YES
INDIRECT
The mRNA vaccine primes HPV16-specific T cells; CD8+ cytotoxic T lymphocytes recognize HPV16 E7 peptides presented on MHC I of infected epithelial cells and induce apoptosis via perforin/granzyme (and Fas–FasL) pathways.
Lipid nanoparticle–encapsulated mRNA therapeutic vaccine encoding HPV16/18 antigens, administered intramuscularly (25/75/150 µg; three doses every 2 weeks). It promotes dendritic-cell antigen presentation (MHC I/II) and robust CD8+ and CD4+ T-cell responses to clear HPV-infected dysplastic cervical epithelial cells and drive lesion regression.
Lipid nanoparticle–encapsulated mRNA encoding HPV16/18 antigens is taken up by host cells, translated into viral proteins, and presented on MHC I/II by dendritic and other antigen-presenting cells. This primes and expands HPV16/18-specific CD8+ cytotoxic and CD4+ helper T cells, promoting immune-mediated clearance of HPV-infected dysplastic cervical epithelial cells and lesion regression.
YES
INDIRECT
The mRNA vaccine primes HPV18 E6–specific CD8+ T cells via dendritic-cell antigen presentation; these T cells recognize E6 peptides on MHC I of infected epithelial cells and kill them via perforin/granzyme (and Fas–FasL) pathways.
Lipid nanoparticle–encapsulated mRNA therapeutic vaccine encoding HPV16/18 antigens, administered intramuscularly (25/75/150 µg; three doses every 2 weeks). It promotes dendritic-cell antigen presentation (MHC I/II) and robust CD8+ and CD4+ T-cell responses to clear HPV-infected dysplastic cervical epithelial cells and drive lesion regression.
Lipid nanoparticle–encapsulated mRNA encoding HPV16/18 antigens is taken up by host cells, translated into viral proteins, and presented on MHC I/II by dendritic and other antigen-presenting cells. This primes and expands HPV16/18-specific CD8+ cytotoxic and CD4+ helper T cells, promoting immune-mediated clearance of HPV-infected dysplastic cervical epithelial cells and lesion regression.
YES
INDIRECT
The mRNA vaccine primes HPV18 E7–specific CD8+ T cells; these CTLs recognize E7 peptide–MHC I on infected epithelial cells and kill them via perforin/granzyme-mediated apoptosis (with CD4+ T-cell help).
Anti-EGFR IgG1 monoclonal antibody that inhibits EGFR signaling to prevent RAS-pathway reactivation and tumor growth.
Chimeric IgG1 monoclonal antibody against EGFR that binds the receptor’s extracellular domain, blocking ligand binding and dimerization to inhibit downstream RAS–RAF–MEK–ERK and PI3K–AKT signaling, suppressing tumor cell proliferation and survival; Fc region may mediate ADCC.
YES
DIRECT
Cetuximab binds EGFR on target cells and engages Fc receptors on immune effectors to induce ADCC (and possibly CDC), killing EGFR+ cells; it also blocks EGFR signaling (antiproliferative).
Chimeric anti-CD20 monoclonal antibody that depletes CD20+ B lymphocytes via complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis; administered weekly until deep B-cell depletion is achieved.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ cells via complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis.
YES
DIRECT
Binding to CD20 leads to complement-dependent cytotoxicity and Fc-mediated ADCC by immune effector cells, and can directly induce apoptosis of CD20+ B cells.